Arca
Skip to content
Tools
Tools

MAPK14: Mitogen-activated protein kinase 14

Serine/threonine kinase which acts as an essential component of the MAP kinase signal transduction pathway.

  • Drugs that act on it: 35
  • Approved: 0
  • In phases 1 to 3: 35
  • Sponsors: 16

Who is on it, and how far along

Every drug ChEMBL records acting on MAPK14, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule 25
  • Other 10

Approved0

    Phase 32

    • ARRY-797
    • Losmapimod

    Phase 218

    • Neflamapimod
    • Pexmetinib
    • Acumapimod
    • AZD-7624
    • BMS-582949
    • Dilmapimod
    • Doramapimod
    • FX-005
    • ITX-5061 free base
    • Pamapimod
    • PF-03715455
    • PG-760564
    • PH-797804
    • Ralimetinib
    • Semapimod
    • TAK-715
    • Talmapimod
    • VX-702

    Phase 115

    • AMG-548
    • AVE-9940
    • AZD-6703
    • GSK-610677
    • LEO-15520
    • LY-3007113
    • PS-516895
    • R-1487
    • RO-3201195
    • RWJ-67657
    • SB-85635
    • SC-80036
    • SCIO-323
    • SD-0006
    • TA-5493

    Sponsors

    Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.

    The landscape

    Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. All act as: MAP kinase p38 alpha inhibitor.
    ARRY-797Phase 3PfizerSmall moleculeInhibitor0
    LosmapimodPhase 3GSKSmall moleculeInhibitor0
    NeflamapimodPhase 2EIP Pharma IncSmall moleculeInhibitor1
    PexmetinibPhase 2Array Biopharma, now a wholly owned subsidiary of PfizerSmall moleculeInhibitor1
    AcumapimodPhase 2Mereo BioPharmaSmall moleculeInhibitor0
    AZD-7624Phase 2AstraZeneca PharmaceuticalsSmall moleculeInhibitor0
    BMS-582949Phase 2Bristol-Myers SquibbSmall moleculeInhibitor0
    DilmapimodPhase 2GSKSmall moleculeInhibitor0
    DoramapimodPhase 2Boehringer Ingelheim PharmaceuticalsSmall moleculeInhibitor0
    FX-005Phase 2Pacira PharmaceuticalsOtherInhibitor0
    ITX-5061 free basePhase 2Kemia, IncSmall moleculeInhibitor0
    PamapimodPhase 2—Small moleculeInhibitor0
    PF-03715455Phase 2PfizerSmall moleculeInhibitor0
    PG-760564Phase 2Procter & GambleOtherInhibitor0
    PH-797804Phase 2PfizerSmall moleculeInhibitor0
    RalimetinibPhase 2Eli LillySmall moleculeInhibitor0
    SemapimodPhase 2Ferring PharmaceuticalsSmall moleculeInhibitor0
    TAK-715Phase 2Takeda Pharmaceuticals USASmall moleculeInhibitor0
    TalmapimodPhase 2Johnson & JohnsonSmall moleculeInhibitor0
    VX-702Phase 2Vertex PharmaceuticalsSmall moleculeInhibitor0
    AMG-548Phase 1—Small moleculeInhibitor0
    AVE-9940Phase 1—OtherInhibitor0
    AZD-6703Phase 1—Small moleculeInhibitor0
    GSK-610677Phase 1GSKOtherInhibitor0
    LEO-15520Phase 1—OtherInhibitor0
    LY-3007113Phase 1—OtherInhibitor0
    PS-516895Phase 1—OtherInhibitor0
    R-1487Phase 1—Small moleculeInhibitor0
    RO-3201195Phase 1—Small moleculeInhibitor0
    RWJ-67657Phase 1—Small moleculeInhibitor0
    SB-85635Phase 1—OtherInhibitor0
    SC-80036Phase 1—OtherInhibitor0
    SCIO-323Phase 1—Small moleculeInhibitor0
    SD-0006Phase 1—Small moleculeInhibitor0
    TA-5493Phase 1—OtherInhibitor0

    Open trials

    The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 2 in all, from ClinicalTrials.gov.
    Clinical Study of Neflamapimod in Patients With Primary Progressive AphasiaNeflamapimodPhase 2Active, not recruitingEIP Pharma IncJun 24, 2025
    Study of ARRY-614 Plus Either Nivolumab or Nivolumab+IpilimumabPexmetinibPhase 1 / Phase 2Active, not recruitingDan ZandbergAug 30, 2019

    Diseases most associated with it

    Open Targets association score, 0 to 1; all associations
    • Neurodegenerative disease0.46
    • Autoimmune disorder of central nervous system0.46
    • Alzheimer disease0.34
    • Parkinson disease0.32
    • Lysosomal storage disease0.30
    • Spondyloarthropathy0.21

    Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL260, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-19. Gene name, function (UniProt Q16539, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

    Esc

    Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

    Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.